PTPRD rs1263643: Genetic Variation and Sleep Architecture
The genetic variant rs1263643 is an intronic single nucleotide polymorphism located within the protein tyrosine phosphatase receptor type D (PTPRD) gene on chromosome 9. Genome-wide and candidate-gene association studies have evaluated this marker for potential statistical links to restless legs syndrome and differences in sleep continuity. While observed in human population cohorts, the overall evidence for a direct causal role remains limited and non-diagnostic.
What each genotype means
Typical Risk Profile
You carry two copies of the major A allele for rs1263643 in the PTPRD gene. In genome-wide association studies, this genotype is not associated with an increased genetic susceptibility to restless legs syndrome or disrupted sleep patterns compared to carrier genotypes. Because evidence strength for this locus is limited, overall sleep traits are heavily influenced by broader environmental, lifestyle, and multi-gene factors.
Carried by approximately 38% to 40% of individuals of European ancestry, and common across many other global populations.
Modestly Increased Susceptibility
You carry one copy of the G risk allele at rs1263643 in the PTPRD gene. Published genome-wide association research has linked this allele to a modest relative increase in the risk of restless legs syndrome and minor disruptions in sleep architecture, though the evidence remains limited and observational. Having this genotype does not cause sleep disorders on its own, as many other lifestyle and genetic factors determine sleep health.
Carried by approximately 45% to 48% of individuals of European ancestry.
Elevated Susceptibility Profile
You carry two copies of the G risk allele at rs1263643 in the PTPRD gene. Large association studies suggest that individuals with this genotype have a statistically higher risk of developing restless legs syndrome compared to non-carriers, although the evidence remains limited and non-diagnostic. This variant accounts for only a minor fraction of overall risk, and carrying two copies does not mean you will develop restless legs syndrome.
Carried by approximately 14% to 16% of individuals of European ancestry, reflecting a minor allele frequency of roughly 0.38.
Genomic Context and the PTPRD Gene
The single nucleotide polymorphism rs1263643 resides within an intronic region of the PTPRD gene, located on the short arm of chromosome 9 (9p23-24). The PTPRD gene encodes protein tyrosine phosphatase receptor type delta, a member of the receptor protein tyrosine phosphatase family. PTPRD is heavily expressed throughout the mammalian central nervous system, particularly in regions involved in motor coordination, sensory processing, and synaptic plasticity. The encoded transmembrane protein functions as a cellular adhesion molecule and signaling regulator, organizing synaptic complexes and guiding neuronal connectivity during development. Because rs1263643 is non-coding and situated deep within an intron, it does not alter the primary amino acid sequence of the phosphatase. Instead, researchers hypothesize that such non-coding variants might exert subtle effects on gene expression, transcript splicing efficiency, or local chromatin architecture. However, precise molecular mechanisms linking this specific base change to altered PTPRD functional levels have not yet been definitively demonstrated in functional assays.
Associated Research: Restless Legs Syndrome and Sleep Patterns
Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a common sensorimotor disorder characterized by an irresistible urge to move the limbs, typically worsening during evening rest and disrupting nighttime sleep. Early genome-wide association studies (GWAS) mapped significant genetic susceptibility loci for restless legs syndrome to chromosomal region 9p23-24 near PTPRD. Subsequent follow-up studies and candidate investigations identified markers in this locus, including rs1263643, as contributing modest statistical differences in RLS susceptibility and metrics of disrupted sleep architecture. In parallel, animal knockout models have illustrated that disruptions in Ptprd can induce altered locomotor activity, altered dopamine-related pathways, and sleep fragmentation. Despite these statistical signals in population cohorts, the evidence strength for rs1263643 specifically remains limited. Rather than acting as a definitive single-gene cause, rs1263643 represents one of several markers in linkage disequilibrium that may slightly modulate baseline polygenic risk alongside environmental, dietary, and iron-homeostasis variables.
Population Frequency and Allelic Distribution
The rs1263643 variant is a common single nucleotide polymorphism observed across multiple worldwide human cohorts surveyed in major genomic repositories like dbSNP and gnomAD. In non-Finnish European reference populations, the minor allele frequency is approximately 0.38, indicating that the alternate allele is widespread in the general public. Because it is common, a substantial proportion of people carry at least one copy of the minor allele without ever developing restless legs syndrome or noticeable sleep fragmentation. Allele frequencies often display variability across different global ancestries, reflecting standard human demographic histories, genetic drift, and geographic population structure. The prevalence of this variant underscores an essential principle of complex trait genomics: high population frequency inherently rules out high-penetrance monogenic pathogenicity, placing rs1263643 in the category of common background modifiers that exert small individual effect sizes.
Clinical Limitations and Personal Interpretation
Understanding a genetic result for rs1263643 requires recognizing what genomic association data can and cannot reveal. This marker cannot diagnose restless legs syndrome, predict sleep quality, or determine whether an individual will experience motor symptoms later in life. Clinically, restless legs syndrome remains a diagnosis based exclusively on standardized neurological and clinical criteria, paired with evaluations of lifestyle, metabolic markers, and serum ferritin levels. If you carry alleles statistically associated with higher symptom frequency, it does not imply disease certainty or clinical severity. Conversely, carrying standard alleles does not grant complete immunity against sleep or sensorimotor disturbances. Consumers should never attempt to alter lifestyle factors, take supplements, or adjust prescription neurological medications based on consumer genotyping data. Any persistent sensations of discomfort, involuntary limb movements, or unrefreshing sleep should be evaluated directly by a qualified healthcare professional or sleep specialist.
How common is this variant?
The rs1263643 polymorphism is common across human populations, exhibiting a minor allele frequency of approximately 0.38 in non-Finnish European reference cohorts.
Frequently asked questions
Does carrying rs1263643 mean I will develop restless legs syndrome?
No. The rs1263643 variant confers only a modest statistical association in population studies and is not a deterministic or diagnostic mutation. Many individuals carrying the minor allele experience normal sleep without ever developing restless legs syndrome.
Can a genetic test for PTPRD rs1263643 replace a clinical sleep evaluation?
No. Clinical sleep disorders, including restless legs syndrome, are diagnosed through medical history, clinical evaluation, and sometimes overnight sleep studies. Genetic markers such as rs1263643 provide statistical research information rather than clinical diagnoses.
What role does the PTPRD gene play in human biology?
PTPRD encodes a receptor-type protein tyrosine phosphatase that is abundant in the central nervous system. It acts as a cell adhesion molecule and signaling component essential for organizing synaptic connections and guiding neuronal development.
Should I adjust medications if I have a risk-associated genotype?
No. Genetic testing for this variant should never be used to initiate, stop, or adjust prescription medications or supplements. Any medical decisions regarding restless legs syndrome or dopaminergic treatments must be made in consultation with a licensed healthcare provider.
Sources & further reading
Educational information only, last refreshed 9/13/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1263643?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29